NBP
NovaBridge Biosciences
$1.56
-5.17%
$183.5M
No data for this timeframe.
Vol
Market Cap$183.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders2 funds
Inst. Value$15.1M
Inst. Activity2 buys / 1 sells
Insider Activity1B / 2S
Insider Net $$520.9K
SEC Reports4
Press Releases2
Recent Activity
Jun 1, 2026
Insider
Xu Cong Claire sold 3,494 shares
SVP, Clinical Development @ $3.94 ($13.8K)
May 30, 2026
Insider
Xu Cong Claire sold 9,382 shares
SVP, Clinical Development @ $0.00 ($0.00)
May 30, 2026
Insider
Xu Cong Claire sold 4,079 shares
SVP, Clinical Development @ $0.00 ($0.00)
May 28, 2026
other
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
<p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq
Apr 22, 2026
SEC
NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer to strengthen its leadership team
6-K — Impact 4/10
Apr 7, 2026
SEC
NovaBridge reported strong clinical progress in 2025 with compelling data for its lead candidates givastomig and VIS-101
6-K — Impact 8/10
Apr 7, 2026
SEC
NovaBridge Biosciences reported strong clinical progress in 2025, highlighted by robust data for its lead candidates giv
20-F — Impact 8/10
Inst.
MORGAN STANLEY — ADD
3,785,502 shares ($15.1M)
Price Targets
$8.00
+403.1% upside
Strong Buy
Current $1.59
Low $7.00
Median $8.00
High $9.00
3 analysts
$7.00
$9.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 16, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 | $-0.23 — $-0.23 | -475% YoY | 1 |
| Next Q | $-0.24 | $-0.24 — $-0.24 | -243% YoY | 1 |
| Current FY | $-0.94 ▼ -203.2% | $-0.94 — $-0.94 | -96% YoY | 1 |
| Next FY | $-1.06 ▼ -140.9% | $-1.06 — $-1.06 | -13% YoY | 1 |
Latest Reports
NEUTRAL
6-K
4/10
NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer to strengthen its leadership team
Apr 22, 2026
BULLISH
6-K
8/10
NovaBridge reported strong clinical progress in 2025 with compelling data for its lead candidates givastomig and VIS-101
Apr 7, 2026
BULLISH
Press
8/10
NovaBridge Biosciences announced positive topline Phase 2a results for VIS-101, a dual VEGF-A X ANG-2 inhibitor, showing
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $15.1M | ADD |
| BANK OF AMERICA CORP | $32.7K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Xu Cong | SELL | $13.8K |
| May 30, 2026 | Xu Cong | M | $0.00 |
| May 30, 2026 | Xu Cong | M | $0.00 |
| May 14, 2026 | Cao Sean | SELL | $42.6K |
| Apr 24, 2026 | Hagler Mark | BUY | $577.3K |
2 institutional holders with $15.1M total value (3,793,721 shares) as of 2025-Q4. Top holders: MORGAN, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 3,785,502 | $15.1M | 99.8% | ADD +69.6% |
| 2 | BANK OF AMERICA CORP /DE/ | 8,219 | $32.7K | 0.2% | ADD +78.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 2,232,040 | 3,785,502 | +69.6% | $15.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 4,617 | 8,219 | +78.0% | $32.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 63,600 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 58,295 | 2,232,040 | +3728.9% | $8.4M | 2025-Q3 |
| UBS Group AG | ADD | 184,845 | 295,078 | +59.6% | $1.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 566 | 4,617 | +715.7% | $17.5K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 113,262 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | TRIM | 318,546 | 184,845 | -42.0% | $447.3K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 210,366 | 113,262 | -46.2% | $274.1K | 2025-Q2 |
| MORGAN STANLEY | ADD | 34,817 | 58,295 | +67.4% | $141.1K | 2025-Q2 |
| UBS Group AG | DOUBLED | 103,054 | 318,546 | +209.1% | $262.5K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 330,206 | 210,366 | -36.3% | $173.3K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 3,543,384 | 34,817 | -99.0% | $28.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 15,431 | 33,300 | +115.8% | $27.4K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 30,647 | 3,543,384 | +11461.9% | $3.0M | 2024-Q4 |
| UBS Group AG | NEW | — | 103,054 | — | $87.6K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 160,589 | 15,431 | -90.4% | $13.1K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 13,880 | 30,647 | +120.8% | $38.0K | 2024-Q3 |
3 unique insiders with 3 transactions. Net insider value: $520.9K ($577.3K bought, $56.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Xu Cong Claire | SVP, Clinical Development | SELL | 3,494 | $3.94 | $13.8K |
| May 30, 2026 | Xu Cong Claire | SVP, Clinical Development | M | 9,382 | $0.00 | $0.00 |
| May 30, 2026 | Xu Cong Claire | SVP, Clinical Development | M | 4,079 | $0.00 | $0.00 |
| May 14, 2026 | Cao Sean Wuxiong | See Remarks | SELL | 21,399 | $1.99 | $42.6K |
| Apr 24, 2026 | Hagler Mark Arnold | See Remarks | BUY | 230,000 | $2.51 | $577.3K |
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 7.0/10.
NEUTRAL
6-K
4/10
NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer to strengthen
Apr 22, 2026
BULLISH
6-K
8/10
NovaBridge reported strong clinical progress in 2025 with compelling data for its lead candidates gi
Apr 7, 2026
BULLISH
20-F
8/10
NovaBridge Biosciences reported strong clinical progress in 2025, highlighted by robust data for its
Apr 7, 2026
BULLISH
PRESS-RELEASE
8/10
NovaBridge Biosciences reported a net loss of $46.3M for FY 2025 with EPS of $(0.21), a significant
Apr 7, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.00 mean target
+403.1% upside
Strong Buy (3.00)
$7.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $1.59 |
| Target Low | $7.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $9.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.23 | $-0.23 | $-0.23 | -475.0% | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-06-30 |
$-0.24 | $-0.24 | $-0.24 | -242.9% | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.94 | $-0.94 | $-0.94 | -95.8% | -203.2% | — | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.06 | $-1.06 | $-1.06 | -12.8% | -140.9% | — | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $0.000 | -0.230 |
| 30d ago | $0.000 | -0.230 |
| 60d ago | $0.000 | -0.230 |
| 90d ago | $0.000 | -0.230 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
other
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
<p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotec
May 18, 2026
short_volume
Short Volume: NBP — 58.7% short (0.4M / 0.6M)
Short: 352,891 | Exempt: 148 | TRF Vol: 601,223 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
earnings
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
<p align="justify">ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global
Apr 1, 2026
earnings_calendar
NBP Q4 2025 Earnings After Market Close — 2026-04-01
Mar 9, 2026
fda
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
<p align="justify">ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biot
Mar 6, 2026
short_interest
FTD: NBP — 427,474 shares ($1.6M) failed to deliver
Settlement: 20260306, Price: $3.64, FTD Value: $1,556,005.36, NOVABRIDGE BIOSCIENCES SPONSOR
Mar 3, 2026
fda
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
<p align="center"><em>VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and dur
Mar 2, 2026
short_interest
FTD: NBP — 178,984 shares ($0.6M) failed to deliver
Settlement: 20260302, Price: $3.28, FTD Value: $587,067.52, NOVABRIDGE BIOSCIENCES SPONSOR